Clinical Evaluation of the Effect of Aficamten on QT / QTc Interval in Healthy Participants
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70218 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Neha Maharao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA. Hauptthemen laut MEDLINE: Electrocardiography, Heart Rate, Long QT Syndrome, Pyrazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aficamten is a next‐in‐class, small‐molecule, cardiac myosin inhibitor in development for treating hypertrophic cardiomyopathy (HCM). This 2‐part study evaluated aficamten's impact on QTc interval in healthy participants. Part A ( n = 10) was an open‐label study to find the appropriate dose for thorough QT (TQT) evaluation in Part B. Part B ( n = 34) was a double‐blind, 3‐way crossover TQT study conducted as per ICH E14 guidance using negative (placebo) and positive (moxifloxacin) controls. A single 50 mg aficamten dose achieved exposures (C max range: 124–1660 ng/mL) comparable to the highest clinical dose (20 mg QD) in obstructive HCM patients (NCT05186818; [C max range: 131–1230 ng/mL]) and was chosen for TQT evaluation. Using concentration‐QT (C‐QT) modeling, the placebo‐ and baseline‐corrected QT interval using Fridericia's correction (ΔΔQTcF) was −1.82 msec (90% CI: −3.43, −0.214) at peak aficamten concentrations (298.3 ng/mL) following the 50 mg dose. The 90% CI upper bound of ΔΔQTcF for aficamten was < 10 msec at all post‐dose time points. Assay sensitivity was established by the 90% CI lower bound for moxifloxacin (ΔΔQTcF) exceeding 5 msec. Aficamten did not cause QTc prolongation (using C‐QT and by time point analyses) within observed plasma concentrations up to 1660 ng/mL (aficamten), 213 ng/mL (metabolite CK‐3834282), and 343 ng/mL (metabolite CK‐3834283). No clinically meaningful effect on electrocardiogram parameters, including absolute QTcF (≤ 450 msec) and change from baseline in QTcF (≤ 30 msec) was noted in aficamten‐treated participants. Aficamten was generally well tolerated. In conclusion, there was no evidence of aficamten‐mediated QTc prolongation across the therapeutic concentration range in a formal TQT study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA.
- Department of Clinical Research, Cytokinetics, Incorporated, South San Francisco, California, USA.
- Department of Clinical Operations, Cytokinetics, Incorporated, South San Francisco, California, USA.
- Department of Biostatistics, Cytokinetics, Incorporated, South San Francisco, California, USA.
- Department of Drug Safety and Pharmacovigilance, Cytokinetics, Incorporated, South San Francisco, California, USA.
ORCID-Profile: Donghong Xu
Zitieren
APA
Maharao, N., Xu, D., Simkins, T. J., Bowles, O., Liu, G., Benattia, Y., Griffith, A., Heitner, S. B., Kupfer, S., & German, P. (2025). Clinical Evaluation of the Effect of Aficamten on QT / QTc Interval in Healthy Participants. Clinical and Translational Science. https://doi.org/10.1111/cts.70218
Vancouver
Maharao N, Xu D, Simkins TJ, Bowles O, Liu G, Benattia Y, et al. Clinical Evaluation of the Effect of Aficamten on QT / QTc Interval in Healthy Participants. Clinical and Translational Science. 2025. doi:10.1111/cts.70218
BibTeX
@article{Maharao2025,
author = {Maharao, Neha and Xu, Donghong and Simkins, Tyrell J and Bowles, Owen and Liu, Genzhou and Benattia, Youcef and Griffith, Adrienne and Heitner, Stephen B and Kupfer, Stuart and German, Polina},
title = {Clinical Evaluation of the Effect of Aficamten on QT / QTc Interval in Healthy Participants},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70218}
}
EUVIMED